S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10
S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10
S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10
S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10

Acasti Pharma (ACST) Stock Forecast, Price & News

+0.02 (+2.16%)
(As of 05/27/2022 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
123,037 shs
Average Volume
276,556 shs
Market Capitalization
$41.94 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive ACST News and Ratings via Email

Sign-up to receive the latest news and ratings for Acasti Pharma and its competitors with MarketBeat's FREE daily newsletter.

Acasti Pharma logo

About Acasti Pharma

Acasti Pharma Inc., a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products for cardiovascular diseases. It is evaluating strategic partnerships for the clinical development of CaPre, an omega-3 phospholipid therapeutic to treat patients with hypertriglyceridemia. The company was incorporated in 2002 and is headquartered in Laval, Canada.


Acasti Pharma Celebrates Rare Disease Day
See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$200 thousand
Book Value
$2.14 per share


Net Income
$-19.68 million
Pretax Margin




Free Float
Market Cap
$41.94 million
Not Optionable

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

1.76 out of 5 stars

Medical Sector

862nd out of 1,424 stocks

Pharmaceutical Preparations Industry

427th out of 681 stocks

Analyst Opinion: 3.5Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Acasti Pharma (NASDAQ:ACST) Frequently Asked Questions

Is Acasti Pharma a buy right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Acasti Pharma in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Acasti Pharma stock.
View analyst ratings for Acasti Pharma
or view top-rated stocks.

Are investors shorting Acasti Pharma?

Acasti Pharma saw a decrease in short interest during the month of May. As of May 15th, there was short interest totaling 1,140,000 shares, a decrease of 14.9% from the April 30th total of 1,340,000 shares. Based on an average daily volume of 155,600 shares, the short-interest ratio is currently 7.3 days. Currently, 3.6% of the shares of the company are short sold.
View Acasti Pharma's Short Interest

When is Acasti Pharma's next earnings date?

Acasti Pharma is scheduled to release its next quarterly earnings announcement on Tuesday, June 28th 2022.
View our earnings forecast for Acasti Pharma

How were Acasti Pharma's earnings last quarter?

Acasti Pharma Inc. (NASDAQ:ACST) released its quarterly earnings data on Thursday, August, 13th. The biopharmaceutical company reported ($0.40) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.48) by $0.08.
View Acasti Pharma's earnings history

When did Acasti Pharma's stock split? How did Acasti Pharma's stock split work?

Acasti Pharma shares reverse split on Tuesday, August 31st 2021. The 1-8 reverse split was announced on Tuesday, August 31st 2021. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, August 31st 2021. An investor that had 100 shares of Acasti Pharma stock prior to the reverse split would have 13 shares after the split.

What price target have analysts set for ACST?

1 equities research analysts have issued 1-year price objectives for Acasti Pharma's stock. Their forecasts range from $6.00 to $6.00. On average, they expect Acasti Pharma's stock price to reach $6.00 in the next twelve months. This suggests a possible upside of 533.6% from the stock's current price.
View analysts' price targets for Acasti Pharma
or view top-rated stocks among Wall Street analysts.

Who are Acasti Pharma's key executives?
Acasti Pharma's management team includes the following people:
  • Ms. Janelle D'Alvise, Pres, CEO, Corp. Sec. & Director (Age 66, Pay $428.04k)
  • Dr. Pierre Lemieux M.D., Ph.D., Co-Founder, COO & Chief Scientific Officer (Age 57, Pay $276.38k)
  • Mr. Brian D. Ford CPA, CA, Chief Financial Officer (Age 63, Pay $364.82k)
  • Dr. Yves Lachance Ph.D., VP of Quality & Compliance
  • Ms. Christine Pelletier, Sr. Director of HR
  • Dr. George Kottayil, Chief Operating Officer of US
  • Mr. Prashant Kohli, VP of Commercial Operations
What other stocks do shareholders of Acasti Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Acasti Pharma investors own include Matinas BioPharma (MTNB), SCYNEXIS (SCYX), Outlook Therapeutics (OTLK), Bionano Genomics (BNGO), Sorrento Therapeutics (SRNE), ADMA Biologics (ADMA), Heat Biologics (HTBX), KushCo (KSHB), Miragen Therapeutics (MGEN) and Aeterna Zentaris (AEZS).

What is Acasti Pharma's stock symbol?

Acasti Pharma trades on the NASDAQ under the ticker symbol "ACST."

How do I buy shares of Acasti Pharma?

Shares of ACST can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Acasti Pharma's stock price today?

One share of ACST stock can currently be purchased for approximately $0.95.

How much money does Acasti Pharma make?

Acasti Pharma has a market capitalization of $41.94 million and generates $200 thousand in revenue each year. The biopharmaceutical company earns $-19.68 million in net income (profit) each year or ($0.38) on an earnings per share basis.

How many employees does Acasti Pharma have?

Acasti Pharma employs 32 workers across the globe.

What is Acasti Pharma's official website?

The official website for Acasti Pharma is www.acastipharma.com.

How can I contact Acasti Pharma?

Acasti Pharma's mailing address is 3009 BOUL. DE LA CONCORDE EAST SUITE 102, LAVAL A8, H7E 2B5. The biopharmaceutical company can be reached via phone at 45-0686-4555, via email at [email protected], or via fax at 45-0687-2272.

This page was last updated on 5/28/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.